| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/1744666X.2016.1139453 |
| P698 | PubMed publication ID | 26735626 |
| P2093 | author name string | Oliver FitzGerald | |
| Muhammad Haroon | |||
| P2860 | cites work | Inflammation and insulin resistance | Q22241893 |
| The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis | Q26862537 | ||
| Inflammation and metabolic disorders | Q27860923 | ||
| Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life | Q48446936 | ||
| Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. | Q51043569 | ||
| A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). | Q51079406 | ||
| High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. | Q51134173 | ||
| Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. | Q51317600 | ||
| A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. | Q51323473 | ||
| Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study. | Q51329205 | ||
| Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis | Q51389843 | ||
| Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. | Q51494850 | ||
| Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. | Q51533754 | ||
| Obesity in early adulthood as a risk factor for psoriatic arthritis. | Q51551961 | ||
| Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. | Q52839367 | ||
| Epidemiology of psoriatic arthritis in the population of the United States. | Q53276933 | ||
| High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. | Q53370558 | ||
| Disease concomitance in psoriasis. | Q54171239 | ||
| Long-term impact of delay in assessment of patients with early arthritis | Q57788506 | ||
| Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab | Q58434824 | ||
| Prevalence of childhood and adult obesity in the United States, 2011-2012 | Q29547370 | ||
| Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Q29619465 | ||
| Peripheral inflammation is associated with remote global gene expression changes in the brain. | Q30578175 | ||
| Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project | Q30968522 | ||
| Eye inflammation in psoriatic arthritis | Q33571301 | ||
| A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort | Q33760824 | ||
| Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women | Q33848992 | ||
| Psoriatic arthritis: Epidemiology, diagnosis, and treatment | Q34047760 | ||
| Obesity and risk of incident psoriatic arthritis in US women | Q34283211 | ||
| Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis: A Bayesian Network Meta-analysis | Q34446260 | ||
| Epidemiology of psoriatic arthritis | Q34531141 | ||
| Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. | Q34558876 | ||
| Alexithymia, anxiety and depression in patients with psoriasis: a case-control study | Q34722040 | ||
| Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease | Q34791372 | ||
| Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis | Q35086458 | ||
| Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. | Q35257745 | ||
| Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype | Q35577152 | ||
| Obesity and the risk of psoriatic arthritis: a population-based study. | Q36820863 | ||
| Psoriasis and uveitis: a literature review | Q36977631 | ||
| Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial | Q37036355 | ||
| CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation | Q37138961 | ||
| Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study | Q37280538 | ||
| Treatment recommendations for psoriatic arthritis. | Q37284516 | ||
| Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations | Q38264287 | ||
| Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease | Q38465974 | ||
| Risk of depression in women with psoriasis: a cohort study | Q38983615 | ||
| The window of opportunity: a relevant concept for axial spondyloarthritis | Q40791296 | ||
| Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). | Q41124783 | ||
| Psoriatic arthritis and hypopyon-iridocyclitis. Possible mechanism of the association of psoriasis and anterior uveitis | Q41309366 | ||
| Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis | Q41932479 | ||
| Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity | Q43472253 | ||
| Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis | Q43474942 | ||
| Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study | Q43727420 | ||
| The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study | Q43955638 | ||
| Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). | Q44948934 | ||
| Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis | Q45244153 | ||
| Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients | Q45736887 | ||
| Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis | Q46085062 | ||
| Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis | Q47203093 | ||
| Depression and anxiety in psoriatic disease: prevalence and associated factors | Q48081198 | ||
| P433 | issue | 4 | |
| P921 | main subject | psoriatic arthritis | Q511097 |
| comorbidity | Q1414874 | ||
| P304 | page(s) | 405-416 | |
| P577 | publication date | 2016-01-06 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Psoriatic arthritis: complexities, comorbidities and implications for the clinic | |
| P478 | volume | 12 |
| Q33876826 | Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis |
| Q97533806 | Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease |
| Q47149662 | KIF3A and IL-4 are disease-specific biomarkers for psoriatic arthritis susceptibility |
| Q37713522 | Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis |
| Q38658975 | Natural Compounds for the Treatment of Psoriatic Arthritis: A Proposal Based on Multi-Targeted Osteoclastic Regulation and on a Preclinical Study |
| Q37638871 | Patterns of clinical nail appearances in patients with cutaneous psoriasis. |
| Q47432586 | Remission in psoriatic arthritis-where are we now? |
| Q40634737 | Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study |
Search more.